Abstract
Mammalian prions are lethal pathogens composed of fibrillar assemblies of misfolded prion protein. Human prion diseases are rare and usually rapidly fatal neurodegenerative disorders, the most common being sporadic Creutzfeldt-Jakob disease (sCJD). Variants in the gene that encodes prion protein (PRNP) are strong risk factors for sCJD, but although the condition has heritability similar to other neurodegenerative disorders, no other risk loci have yet been confirmed. By genome-wide association in European ancestry populations, we found three replicated loci (cases n=5208, within PRNP, STX6, and GAL3ST1) and two further unreplicated loci were significant in gene-wide tests (within PDIA4, BMERB1). Exome sequencing in 407 sCJD cases, conditional and transcription analyses suggest that associations at PRNP and GAL3ST1 are likely to be caused by common variants that alter the protein sequence, whereas risk variants in STX6 and PDIA4 associate with increased expression of the major transcripts in disease-relevant brain regions. Alteration of STX6 expression does not modify prion propagation in a neuroblastoma cell model of mouse prion infection. We went on to analyse the proteins histologically in diseased tissue and examine the effects of risk variants on clinical phenotypes using deep longitudinal clinical cohort data. Risk SNPs in STX6, a protein involved in the intracellular trafficking of proteins and vesicles, are shared with progressive supranuclear palsy, a neurodegenerative disease associated with the misfolded protein tau. We present the first evidence of statistically robust associations in sporadic human prion disease that implicate intracellular trafficking and sphingolipid metabolism.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust and Medical Research Council. The kuru studies were initially funded by a Wellcome Trust Principal Research Fellowship in the Clinical Sciences to JC, and since 2001, and all other aspects of the work by the Medical Research Council. Several authors at UCL/UCLH receive funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. Some of this work was supported by the Department of Health funded National Prion Monitoring Cohort study. SJC receives an NHMRC Practitioner Fellowship (ID# APP1105784). Tze How Mok is supported by a Fellowship award from Alzheimer’s Society, UK (grant number 341 (AS-CTF-16b-007)) and CJD Support Network UK Research Support Grants. Funding for the collection of Polish samples for study was provided Medical University of Lodz. The Italian national surveillance of Creutzfeldt-Jakob disease and related disorders is partially supported by the Ministero della Salute, Italy. The German National Reference Centre for TSE is funded by grants from the Robert-Koch-Institute. The Dutch National Prion Disease Registry is funded by the National Institute for Public Health and the Environment (RIVM), which is part from the Ministry for Health, Welfare and Sports, The Netherlands. PS-J was supported by Instituto de Salud Carlos III [Fondo de Investigación Sanitaria, PI16/01652] Accion Estrategica en Salud integrated in the Spanish National I+D+i Plan and financed by Instituto de Salud Carlos III (ISCIII) – Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER – “Una Manera de Hacer Europa”). The study on Italian controls was supported by the Ministero dell’Istruzione, dell’Università e della Ricerca – MIUR project “Dipartimenti di Eccellenza 2018 – 2022” (n° D15D18000410001) to the Department of Medical Sciences, University of Torino (G.M.) and the AIRC “ Associazione Italiana per la Ricerca sul Cancro (IG 2018 Id.21390 to G.M.). The Three-City Study was performed as part of a collaboration between the Institut National de la Santé et de la Recherche Médicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthélabo. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and Bourgogne Regional Councils, Agence Nationale de la Recherche, ANR supported the COGINUT and COVADIS projects. Fondation de France and the joint French Ministry of Research/INSERM «Cohortes et collections de données biologiques» programme. Lille Génopôle received an unconditional grant from Eisai. This work was also funded by the Pasteur Institut de Lille, the Lille Métropole Communauté Urbaine, the Haut-de France council, the European Community (FEDER) and the French government’s LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer’s disease). The French National Surveillance Network for Creutzfeldt-Jakob disease is supported by Santé Publique France.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics will be made available through the GWAS catalogue at NHGRI-EBI.
